Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for Pfizer Inc.�
+0.01 (0.03%)
After Hours: 32.25 +0.27 (0.84%)
Nov 25, 9:19AM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 28.47 - 36.46
Open     -
Vol / Avg. 122,317.00/37.92M
Mkt cap 197.35B
P/E 23.93
Div/yield 0.28/3.50
EPS 1.34
Shares 6.17B
Beta 0.90
Inst. own 74%
Jan 25, 2016
Q4 2015 Pfizer Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 23, 2015
Pfizer Inc to Discuss Proposed Combination with Allergan Plc
Nov 11, 2015
Pfizer Inc at Credit Suisse Healthcare Conference
Nov 2, 2015
Pfizer Inc at �EBD BIO Europe- Fall
Oct 27, 2015
Q3 2015 Pfizer Inc Earnings Call
Oct 27, 2015
Q3 2015 Pfizer Inc Earnings Release
Oct 1, 2015
Pfizer Inc at Leerink Partners Immuno-Oncology Roundtable
Sep 17, 2015
Pfizer Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 17.62% 18.39%
Operating margin 23.74% 25.66%
EBITD margin - 40.72%
Return on average assets 5.15% 5.34%
Return on average equity 12.73% 12.32%
Employees 78,300 -
CDP Score - 92 B


235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women's/men's health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 57
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 56
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 54
Bio & Compensation  - Reuters
John D Young Group President - Global Established Pharma Business
Age: 50
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 53
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 59
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters